A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
Phase of Trial: Phase III
Latest Information Update: 14 Jan 2018
At a glance
- Drugs Olaparib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms POLO
- Sponsors AstraZeneca
- 16 Aug 2017 Planned End Date changed from 17 Aug 2018 to 31 Jul 2019.
- 16 Aug 2017 Planned primary completion date changed from 31 Oct 2017 to 31 May 2018.
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology